Helmy Eltoukhy believes a liquid biopsy for early cancer screening could be technologically feasible within one to two years, but clinical studies are the primary gating item.

Guardant Health's liquid biopsy test has a sensitivity of approximately 40% for brain cancers, which is lower than the 85% for most other cancers due to the blood-brain barrier.

Guardant Health's proprietary technology improves the accuracy of DNA sequencing by 1,000 to 10,000-fold compared to off-the-shelf sequencers.

Traditional tissue biopsies for lung cancer have a 19% complication rate.

In clinical studies, Guardant Health's liquid biopsy test detects 85% of the genomic alterations found in a tissue biopsy, while a tissue biopsy only detects 80% of what the liquid biopsy finds.

Guardant Health is processing more than 20,000 patient samples per year.

Approximately 15% of Guardant Health's test volume comes from serial testing of repeat patients.

The oncology diagnostics market is estimated to be a $30 billion market.

Guardant Health launched its liquid biopsy product, Guardant360, in June 2014.

The average cost of a traditional tissue biopsy for lung cancer is $14,000.

The fastest-growing part of Guardant Health's business is its work with pharmaceutical companies to screen patients for clinical trials.

Guardant Health's Guardant360 test is intended for the approximately one million late-stage cancer patients in the U.S.

Guardant Health's long-term vision is to create a cancer screening test that can be administered as part of a routine annual physical.

The diagnostic accuracy of Guardant Health's liquid biopsy is 99.3% concordant with tissue biopsies for the mutations it detects.

The Guardant360 test has a list price of approximately $5,000, compared to a total cost of $15,000 to $20,000 for a traditional tissue biopsy and subsequent genomic profiling.

Guardant Health believes it genomically sequences more cancer patients than Memorial Sloan Kettering and MD Anderson Cancer Center combined.

Guardant Health has a partnership with LabCo, a part of Synlab, for distribution of its tests in most of Europe and a large portion of South America.

Guardant Health's test is used by approximately 2,000 of the 10,000 oncologists in the United States.